A Study of Mosliciguat in PH-ILD
NCT: NCT06635850 · ACTIVE_NOT_RECRUITING
광고
NCT IDNCT06635850
상태ACTIVE_NOT_RECRUITING
시작일2024-10-29
SponsorPulmovant, Inc. (INDUSTRY)
First posted
Last updated
간략 요약
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
공식 출처
ClinicalTrials.gov에서 보기 →데이터는 ClinicalTrials.gov API에서 제공됩니다. 최신 상태는 공식 기록을 확인하세요.